Next 10 |
home / stock / lly / lly articles
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says t...
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 15 years by 10.71% on an annualized basis producing an average annual return ...
Wednesday, Eli Lilly And Co (NYSE:LLY) released topline results from SURMOUNT-OSA phase 3 trials of tirzepatide in obstructive sleep apne...
U.S. District Judge Roy Altman ruled that the drugmaker Eli Lilly And Co (NYSE:LLY) cannot rely on state law to stop a compound...
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evid...
At the Needham Healthcare Conference, Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) highlighted why they remain excited about Baqsimi, the ...
Jim Cramer, CNBC’s market commentator, recently shared his insights on Tuesday’s market activity. He believes that stocks like NVIDIA C...
In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess comp...
After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company (NYSE:LLY) stock h...
News, Short Squeeze, Breakout and More Instantly...
Eli Lilly and Company Company Name:
LLY Stock Symbol:
NYSE Market:
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says t...
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 15 years by 10.71% on an annualized basis producing an average annual return ...
2024-04-18 10:00:06 ET Evan David Seigerman from BMO Capital issued a price target of $900.00 for LLY on 2024-04-18 08:39:00. The adjusted price target was set to $900.00. At the time of the announcement, LLY was trading at $748.4048. The overall price target consensus i...